You are here: Home: Special Report: 21st Annual Miami Breast Cancer Conference 2004:
B: HER2 Assessment: Select publications
Select publications
Paik S et al. Real-world performance of HER2 testing National Surgical Adjuvant Breast and Bowel Project experience. J Natl CancerInst 2002;94:852-4. Abstract
Paik S et al. Successful quality assurance program for HER2 testing in the NSABP trial for Herceptin®. Breast Cancer ResTreat 2002;76(Suppl 1); Abstract 9.
Perez EA et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 2002;77:148-54. Abstract.
Press MF et al. Comparison of HER-2/neu status determined by fluorescence in situ hybridization (FISH) in the BCIRG central laboratories with HER-2/neu status determined by immunohisto-chemistry or FISH in outside laboratories. Breast Cancer ResTreat 2002;76(Suppl 1); Abstract 238.
Press MF et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002;20:3095-105. Abstract
Rhodes A et al. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: A comparative study involving results from laboratories in 21 countries. Am J Clin Pathol 2002; 118(3):408-17. Abstract
Roche PC et al. Concordance between local and central laboratory HER2 testing in the Breast Intergroup Trial N9831. J Natl Cancer Inst 2002;94:855-7. Abstract
Wang S et al. Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol 2001;116:495-503. Abstract
|
